^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
cosibelimab (CK-301)
i
Other names: CK-301, TG-1501, CK 301, CK301, TG 1501, TG1501
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Fortress, TG Therap
Drug class:
PD-L1 inhibitor
Related drugs:
3ms
CONTERNO: Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab (CK-301) in First Line Metastatic Non-squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
P3, N=25, Terminated, Checkpoint Therapeutics, Inc. | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
cisplatin • carboplatin • pemetrexed • dexamethasone • cosibelimab (CK-301)
1year
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers (clinicaltrials.gov)
P1, N=500, Recruiting, Checkpoint Therapeutics, Inc. | Trial completion date: Dec 2023 --> Dec 2024
Trial completion date • Metastases
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
cosibelimab (CK-301)
over1year
Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer. (PubMed, Front Med (Lausanne))
In recent years, the combination therapy of nivolumab plus ipilimumab has gained ground in studies for its survival and response rate benefits in patients with advanced melanoma...On the contrary, in advanced and metastatic BCC, successful therapeutic strategies, such as vismodegib and sonidegib, are based on the inhibition of aberrant activation of the Hedgehog signaling pathway...In patients with locally advanced or metastatic SCC, who are not candidates for surgery or radiotherapy, anti-PD1 agents such as cemiplimab, pembrolizumab, and cosibelimab (CK-301) have shown significant results in terms of response rate. PD-1/PD-L1 inhibitors, such as avelumab, have also been used in Merkel carcinoma, achieving responses in half of the patients with advanced disease...Two of the most promising molecules used in combination with immunotherapy are cavrotolimod (a Toll-like receptor 9 agonist) and a Toll-like receptor 7/8 agonist...Neoadjuvant treatment with cemiplimab in CSCCs and nivolumab in MCCs has shown promising results. Despite the successes of these new drugs, the new challenges ahead will be to select patients who will benefit from these treatments based on biomarkers and parameters of the tumor microenvironment.
Review • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • IL15 (Interleukin 15)
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Bavencio (avelumab) • Libtayo (cemiplimab-rwlc) • Erivedge (vismodegib) • Odomzo (sonidegib) • cavrotolimod (AST-008) • cosibelimab (CK-301)
almost2years
CONTERNO: Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab (CK-301) in First Line Metastatic Non-squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
P3, N=25, Terminated, Checkpoint Therapeutics, Inc. | N=560 --> 25 | Trial completion date: Dec 2025 --> Dec 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Dec 2022; Regional political conflict
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
cisplatin • carboplatin • pemetrexed • dexamethasone • cosibelimab (CK-301)
2years
CONTERNO: Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab (CK-301) in First Line Metastatic Non-squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
P3, N=560, Active, not recruiting, Checkpoint Therapeutics, Inc. | Recruiting --> Active, not recruiting | Trial completion date: May 2025 --> Dec 2025 | Trial primary completion date: May 2024 --> Dec 2024
Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
cisplatin • carboplatin • pemetrexed • dexamethasone • cosibelimab (CK-301)
almost3years
CONTERNO: Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab (CK-301) in First Line Metastatic Non-squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
P3, N=560, Recruiting, Checkpoint Therapeutics, Inc. | Not yet recruiting --> Recruiting | Initiation date: Sep 2021 --> Dec 2021
Enrollment open • Trial initiation date • Combination therapy
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
cisplatin • carboplatin • pemetrexed • dexamethasone • cosibelimab (CK-301)
almost3years
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers (clinicaltrials.gov)
P1, N=500, Recruiting, Checkpoint Therapeutics, Inc. | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Jul 2021 --> Nov 2021
Trial completion date • Trial primary completion date
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
cosibelimab (CK-301)
3years
CONTERNO: Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab (CK-301) in First Line Metastatic Non-squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
P3, N=560, Not yet recruiting, Checkpoint Therapeutics, Inc. | Initiation date: Jun 2021 --> Sep 2021
Clinical • Trial initiation date • Combination therapy
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
cisplatin • carboplatin • pemetrexed • dexamethasone • cosibelimab (CK-301)
over3years
CONTERNO: Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab (CK-301) in First Line Metastatic Non-squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
P3, N=560, Not yet recruiting, Checkpoint Therapeutics, Inc.
Clinical • New P3 trial • Combination therapy
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
cisplatin • carboplatin • pemetrexed • dexamethasone • cosibelimab (CK-301)
Share via
